[Clinical proteomics: towards early detection of cancers].
A key challenge in clinical proteomic of cancer is the identification of biomarkers that would allow early detection, diagnosis and monitor progression of the disease to improve long-term survival of patients. Recent advances in proteomic instrumentation and computational methodologies offer unique chance to rapidly identify these new candidate markers or pattern of markers. The combination of retentate affinity chromatography and surfaced-enhanced laser desorption/ionization time-of-flight (SELDI-TOF) mass spectrometry is one of the most interesting new approaches for cancer diagnostic using proteomic profiling. This review aims to summarize the results of studies that have used this new technology method for the early diagnosis of human cancer. Despite promising results, the use of the proteomic profiling as a diagnostic tool brought some controversies and technical problems and still requires some efforts to be standardised and validated.
Solassol
Jérôme
J
Laboratoire de Biologie cellulaire et hormonale, INSERM U.540, Hôpital Arnaud de Villeneuve, 191 avenue du Doyen Giraud, 34295 Montpellier Cedex 5, France.
Boulle
Nathalie
N
Maudelonde
Thierry
T
Mangé
Alain
A
D014408:Biomarkers, Tumor / Q000097:blood; D005260:Female; D006801:Humans; D008297:Male; D009369:Neoplasms / Q000175:diagnosis* / Q000235:genetics; D040901:Proteomics
D014408:Biomarkers, Tumor